PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

Status Terminated

Clinical Trial Summary

This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584. Subjects who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or non-compliance with the protocol requirement.

Clinical Trial Description

In order for tumors to grow and spread to other parts of the body, they need to have a growing blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. In adults, blood vessel cells normally divide very rapidly. It is thought that PTK787/ZK222584 may interfere with the growth of new blood vessels. A drug that interferes with the growth of new blood vessels might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Since normal blood vessel cells divide very rapidly, it might be possible to stop tumor growth without harming normal tissues.

The purpose of this study is to find out if an investigational drug, PTK787/ZK 222584 is safe and effective in treating relapsed or refractory diffuse large cell lymphoma. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00511043
Study type	Interventional
Source	Duke University
Contact
Status	Terminated
Phase	Phase 2
Start date	November 2005
Completion date	June 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00379574` - Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL	Phase 1/Phase 2
Terminated	`NCT00514722` - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies	N/A
Completed	`NCT00169130` - ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma	Phase 2/Phase 3
Terminated	`NCT00135499` - R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma	Phase 3
Completed	`NCT00823719` - Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)	Phase 2
Completed	`NCT01014208` - Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma	Phase 3
Completed	`NCT00001237` - Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas	Phase 2
Terminated	`NCT00498914` - Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects	Phase 2
Completed	`NCT00137995` - R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma	Phase 3
Completed	`NCT00498043` - A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma	Phase 2
Completed	`NCT00622388` - Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant	Phase 2
Completed	`NCT00561379` - Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab	N/A